CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2026)
CG Oncology's (CGON) quarterly Total Non-Current Liabilities came in at $42.0 million in Q1 2026, up 12.84% on a QoQ basis from $37.2 million in Q4 2025.
CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Total Non-Current Liabilities data on file, last reported at $42.0 million in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (changed N/A YoY) and the FY2025 annual result came in at $37.2 million, up 73.9% from the prior year.
- Total Non-Current Liabilities improved to $42.0 million in Q1 2026, from $37.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $42.0 million in Q1 2026 to a low of $14.1 million in Q4 2023.
- A 4-year average of $30.7 million and a median of $37.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 51.42% — and 2025, when it jumped 73.9%.
- Tracing CGON's Total Non-Current Liabilities over 4 years: stood at $14.1 million in 2023, then jumped by 51.42% to $21.4 million in 2024, then jumped by 73.9% to $37.2 million in 2025, then grew by 12.84% to $42.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $42.0 million (Q1 2026), $37.2 million (Q4 2025), and $38.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 55.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.38 Mn |
| Mar 31, 2026 | 42.03 Mn |
| Dec 31, 2025 | 37.25 Mn |
| Sep 30, 2025 | 38.47 Mn |
| Dec 31, 2024 | 21.42 Mn |
| Dec 31, 2023 | 14.15 Mn |